Zydus Lifesciences Limited
ZYDUSLIFE
Classifica tra le azioni
#1751
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Prezzo delle azioni
$12.30
Capitalizzazione di mercato
$12.27B
Variazione (1 giorno)
0.06%
Variazione (1 anno)
8.33%
Paese
IN
Scambia Zydus Lifesciences Limited (ZYDUSLIFE)
Categoria
Healthcare
Rapporto P/S per Zydus Lifesciences Limited (ZYDUSLIFE)
Rapporto P/S al October 2026 TTM: 3.94
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Zydus Lifesciences Limited, il rapporto P/S attuale (TTM) è 3.94. Alla fine del 2024, era pari a 5.18.
Storico del rapporto P/S per Zydus Lifesciences Limited da 2004 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 3.94 | 3.72% |
| 2025 | 3.80 | -26.59% |
| 2024 | 5.18 | 74.98% |
| 2023 | 2.96 | 22.93% |
| 2022 | 2.41 | -23.84% |
| 2021 | 3.16 | 59.50% |
| 2020 | 1.98 | -28.35% |
| 2019 | 2.76 | -18.65% |
| 2018 | 3.40 | -29.18% |
| 2017 | 4.80 | 45.51% |
| 2016 | 3.30 | -20.00% |
| 2015 | 4.12 | 41.90% |
| 2014 | 2.91 | 22.44% |
| 2013 | 2.37 | -22.24% |
| 2012 | 3.05 | -15.77% |
| 2011 | 3.62 | 18.07% |
| 2010 | 3.07 | 136.85% |
| 2009 | 1.30 | -0.58% |
| 2008 | 1.30 | -40.68% |
| 2007 | 2.20 | -59.66% |
| 2006 | 5.45 | 25.08% |
| 2005 | 4.35 | -50.77% |
| 2004 | 8.84 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 79.07% |
IN
|
